Medical bottles and syringe are visible to the Novo Nordisk logo displayed on the screen in the background.
Nurphoto | Nurphoto | Getty images
Actions Novo Nordisk He collapsed on Monday, after the Danish pharmaceutical giant said that his new generation drug for slimming helped obese or overweight adult patients with type 2 diabetes by 15.7% of their weight after 68 weeks.
The company's shares fell by 6.3% at 11:22 in London.
Novo Nordisk, which produces a fierce popular medicine for slimming in Wegova, Forecast earlier Weight loss 25% for patients taking Cagrisema. In another result of the late sample published in December, the company stated that Cagrisema helped patients reduce their weight by 22.7% in this test.
Cagrisema is examined by Novo Nordisk as a medicine for adults who are overweight or obesity, as well as the treatment of adults with type 2 diabetes. The company is currently expecting to submit an application for regulatory approval of Cagrisema in the first quarter of 2026.
USA rival shares Eli LillyWhich makes Mounjaro the medicine rose briefly after Novo Nordisk's update on Monday, but in London it dropped by 1.2% to 11:34.
Markets hope Cagrisema It can become a new generation medicine. Treatment, injected once every week, is a combination of Cagrilintide and semaglutide – an active ingredient in Wegova.
In the study of the Cagrisema phase 3 had 1,206 participants with a medium output body weight of 102 kg (225 pounds).
Despite the negative response to investors' results on Monday, Novo Nordisk advertised “excellent weight loss” achieved by people taking Cagrisa compared to those who, taking into account placebo, which dropped only 3.1% of their weight for 68 weeks.
Novo Nordisk also said that the drug seemed to have a “safe and well -tolerated profile”, with the most common side effect to moderate gastrointestinal symptoms. The company noticed that they decreased over time.
Last weekNovo Nordisk has launched an internet pharmacy, Novocare to allow consumers to buy Wegova directly from the company at a reduced price of 499 USD per month.
Drug success in slimming Wegova and Ozmpic helped Novo Nordisk One of the most valuable companies in the world.